Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director | May 29, 2026 | June 02, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2036-06-18 | Direct | 144,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 144,400 · Balance 144,400 F1: Vesting in 12 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting in 12 equal monthly installments.
Merck & Co., Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 14,824.5202 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 1,853.0997 · Balance 14,824.5202 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 100 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 100 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,640 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 18,640 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 20:33 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 144,400 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001737287-26-000019 · wk-form4_1782246783.xml · derivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,400 Underlying: Common Stock · 144,400 shares Expires 2036-06-18 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments. Read SEC document |
| June 04, 2026 Filed Jun 6, 2026 00:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-260261 · ownership.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,640 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000155 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,824.5202 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 7,239 | $17.02 | $123,207.78 |
DisclosureSEC source: 0001193125-26-106701 · ownership.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,765 F1 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 01:03 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 95,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000073 · wk-form4_1750726995.xml · derivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 17:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,863.0921 | $76.84 | $220,000.00 |
DisclosureSEC source: 0001127602-25-016360 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,539.8325 Underlying: Common Stock · 2,863.0921 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 4,792 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037525 · ownership.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires 2035-03-10 Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037525 · ownership.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,004 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:35 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 191,082 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001593968-24-000841 · primary_01.xml · derivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,082 Underlying: Common Stock · 191,082 shares Expires 2034-06-05 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 18:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,752.4295 | $125.54 | $220,000.00 |
DisclosureSEC source: 0001127602-24-017574 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,379.7044 Underlying: Common Stock · 1,752.4295 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,135 | $122.96 | $385,479.60 |
DisclosureSEC source: 0000950170-24-027497 · ownership.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,621 F1 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,679 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026614 · ownership.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 3,679 shares Expires 2034-03-01 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026614 · ownership.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,756 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:07 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 10,000 | $4.29 | $42,855.00 |
DisclosureSEC source: 0001593968-23-001153 · primary_01.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.27 to $4.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:57 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 116,120 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001593968-23-001008 · primary_01.xml · derivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,120 Underlying: Common Stock · 116,120 shares Expires 2033-06-13 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments Read SEC document |
| May 26, 2023 Filed May 31, 2023 18:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,980.7329 | $111.07 | $220,000.00 |
DisclosureSEC source: 0001127602-23-017171 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,430.3599 Underlying: Common Stock · 1,980.7329 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,257 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017394 · doc4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2033-03-06 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017394 · doc4.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,910 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024. Read SEC document |
| November 17, 2022 Filed Nov 22, 2022 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 858 | $109.92 | $94,311.36 |
DisclosureSEC source: 0001209191-22-058283 · doc4.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,387 F1 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 20:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 54,487 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001737287-22-000053 · primary_doc.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,487 Underlying: Common Stock · 54,487 shares Expires 2032-07-08 F1 · derivative.exercise_date: 1. The shares subject to the stock option shall vest in a series of 36 successive equal installments measured from the date of grant. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 20:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 35,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-22-000053 · primary_doc.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,328 Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,363.5582 | $93.08 | $220,000.00 |
DisclosureSEC source: 0001127602-22-016164 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,297.517 Underlying: Common Stock · 2,363.5582 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,077 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017713 · doc4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 Underlying: Common Stock · 5,077 shares Expires 2032-03-07 Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017713 · doc4.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,245 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 7, 2023. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 8,238 | $0.00 Strike: $83.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065315 · doc4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,238 Underlying: Common Stock · 8,238 shares Expires 2031-11-16 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning November 16, 2022. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065315 · doc4.xml · nonDerivative · entry 1 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,292 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning November 16, 2022. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 17:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,635.3933 | $75.89 | $200,000.00 |
DisclosureSEC source: 0001127602-21-018658 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755.2908 Underlying: Common Stock · 2,635.3933 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 119.8975 | $76.23 | $9,139.79 |
DisclosureSEC source: 0001127602-21-010907 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119.8975 Underlying: Common Stock · 119.8975 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.